678 filings
ARS
2023 FY
NSPR
InspireMD Inc
18 Apr 24
Annual report to shareholders
4:25pm
DEFA14A
NSPR
InspireMD Inc
18 Apr 24
Additional proxy soliciting materials
4:20pm
DEF 14A
NSPR
InspireMD Inc
Definitive proxy
18 Apr 24
4:15pm
8-K
NSPR
InspireMD Inc
2 Apr 24
Departure of Directors or Certain Officers
9:14am
8-K
NSPR
InspireMD Inc
26 Mar 24
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
7:56am
8-K
xnva q2wg
6 Mar 24
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
7:07am
8-K
qnxyx9tu
31 Jan 24
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
8:09am
S-8
e6jrtib4jdnqzyz4fei2
2 Jan 24
Registration of securities for employees
5:16pm
8-K
84fy fqp94
20 Dec 23
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuardTM Neuroprotection System
7:22am
8-K
l5nza7rx2
27 Nov 23
Regulation FD Disclosure
7:06am
8-K
sn8co
6 Nov 23
InspireMD Reports Third Quarter 2023 Financial Results and Provides
7:07am
8-K
qydm45zq1fxp48d1aql5
1 Nov 23
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS
2:31pm
8-K
9oi ktwjf2
12 Oct 23
Regulation FD Disclosure
8:24am
8-K
du1dz lcp14dbq6e
6 Oct 23
Departure of Directors or Certain Officers
4:15pm
S-8
kz2k11gibuiyyj9ea8g
6 Oct 23
Registration of securities for employees
11:25am
8-K
3jxrk5ahjj w8
13 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
q65fjg
31 Aug 23
InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23
8:10am
8-K
v721c o40
8 Aug 23
InspireMD Reports Second Quarter 2023 Financial Results and Provides
7:09am